TARS250117P50000
- 2.39
- -1.86-43.76%
Tarsus Pharmaceuticals Newsroom
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $65
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating
A Quick Look at Today's Ratings for Tarsus Pharmaceuticals(TARS.US), With a Forecast Between $65 to $84
Tarsus Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Tarsus Pharmaceuticals Analyst Ratings
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $60
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $60
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $60
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $63
Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Neurocrine (NBIX) and Tarsus Pharmaceuticals (TARS)
LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $67
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $63
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $63
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $60
Tarsus Pharmaceuticals Analyst Ratings
Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $63 From $61, Maintains Outperform Rating
LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $67
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $61